Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte Gains 44% in a Year: What's Driving the Stock?
08:26am, Monday, 06'th Jan 2025
VCYT is gaining shares due to the strength of its Afirma and Decipher tests.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
08:21am, Friday, 27'th Dec 2024
Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.
Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks?
01:57pm, Thursday, 19'th Dec 2024
The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.
4 Healthcare Technology Innovators to Invest in Before the New Year
12:00pm, Thursday, 19'th Dec 2024
Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025
04:01pm, Monday, 16'th Dec 2024
The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth.
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave
12:16pm, Monday, 16'th Dec 2024
MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and su
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
03:16am, Thursday, 12'th Dec 2024
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
10:00am, Wednesday, 11'th Dec 2024
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
5 Medical Device Stocks That Survived the 2024 Market Volatility
08:55am, Wednesday, 11'th Dec 2024
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
04:05pm, Thursday, 05'th Dec 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
11:55am, Thursday, 07'th Nov 2024
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
10:49pm, Wednesday, 06'th Nov 2024
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
07:10pm, Wednesday, 06'th Nov 2024
Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.
Veracyte to Participate in Upcoming Investor Conferences
05:00pm, Wednesday, 30'th Oct 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthc
Veracyte: Revolutionizing Noninvasive Cancer Diagnostics
11:38am, Monday, 21'st Oct 2024
In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).
